Clinical trials: Metabolic Dysfunction-associated Steatohepatitis (MASH)
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)
- Trial name
- NCT07848191
- Testing
- Rezdiffra, Resmetirom, ACTOS/pioglitazone
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Liver Cancer, Adult, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll adult patients with liver diseases such as metabolic-dysfunction…
- Conditions
- Liver Cancer, Adult, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Obesity and Overweight
- Trial name
- TRE+HE (NCT06824974)
- Testing
- Time-restricted eating plus healthy diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
- Trial name
- NCT06318169
- Testing
- Pegozafermin
- Where
- 370 sites in United States, Argentina and 25 more
- Volunteers
- 1,350 people
- Sponsor
- Hoffmann-La Roche
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Trial name
- NASHGEN-2 (NCT05519475)
- Testing
- ALN-HSD
- Where
- 71 sites in United States, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors
The Development of MASLD Among Survivors of Breast or Colorectal Cancer
A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly.
- Conditions
- Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- EVALUATE (NCT07280143)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Bern
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic…
- Trial name
- NCT06836609
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 132 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-associated Steatotic Liver Disease
Guerbet Liver Fibrosis
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1…
- Trial name
- NCT06703450
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of this study is to find out how well a medicine called BI 770371 is tolerated.
- Trial name
- NCT06675929
- Testing
- BI 770371
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- Boehringer Ingelheim
Healthy, Metabolic Dysfunction-associated Steatohepatitis
A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PKs) of BI 3804379 in healthy male and female participants and in stable patients with advanced liver fibrosis due to MASH following…
- Trial name
- NCT06575400
- Testing
- BI 3804379
- Where
- Belgium
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Metabolic Dysfunction-Associated Steatohepatitis(MASH)
Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults
This is a first-in-human, Phase I, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QL2401 following single and multiple…
- Trial name
- NCT07331545
- Testing
- QL2401
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected MASH.
- Conditions
- Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- MASH (NCT06939816)
- Testing
- Vonafexor low dose, Vonafexor high dose
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Enyo Pharma
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
AGED Diagnostics Clinical Validation Study
Validation of Blood-Based Tests for the Diagnosis of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Liver Fibrosis: This study aims to validate two investigational blood tests developed by AGED Diagnostics for the…
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Fibrosis and Cirrhosis of Liver, MetALD
- Trial name
- NCT07867574
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Active Genomes Expressed Diagnostics, Corp
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04906421
- Testing
- TVB-2640
- Where
- 117 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Sagimet Biosciences Inc.
Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
- Trial name
- NCT07632677
- Testing
- iLivTouch (Vibration-controlled transient elastography)
- Where
- 22 sites in China
- Volunteers
- 10,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant.
- Trial name
- NCT07335601
- Testing
- Resmetirom
- Where
- 17 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Resmiterom Efficacy & Safety in Patients With MASH
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
- Trial name
- REZMASH (NCT07249788)
- Testing
- Resmetirom
- Where
- Pakistan
- Volunteers
- 165 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH)
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches.
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
- Trial name
- METAfoie (NCT06764056)
- Testing
- semaglutide, Diet
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver
Samsung S-Viscosity vs Canon Dispersion Slope in Steatotic Liver Disease (SAVID-SLD)
Steatotic liver disease (SLD) is one of the most common chronic liver diseases worldwide. Distinguishing simple steatosis from metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis is clinically…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver, Liver Fibrosis
- Trial name
- SAVID-SLD (NCT07530419)
- Testing
- Samsung Medison HERA W12 (R30) with S-Shearwave platform, Canon Aplio i800 with Dispersion Slope Imaging
- Where
- South Korea
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
MASH - Metabolic Dysfunction-Associated Steatohepatitis
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and…
- Trial name
- NCT07463287
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai East Hospital